THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

~~1. A method of preventing and/or treating chronic traumatic encephalopathy, the method including administering to the subject an effective amount of a substance P receptor antagonist.~~

2. A ~~method~~ use according to claim 1, wherein the disease, condition or state is due to tau hyperphosphorylation associated with chronic traumatic encephalopathy.

3. A ~~method~~ use according to claims 1 or 2, wherein the substance P receptor antagonist is a NK1 receptor antagonist, a NK2 receptor antagonist, or a NK3 receptor antagonist.

4. A ~~method~~ use according to claim 3, wherein the NK1 receptor antagonist is selected from one or more of the group consisting of Casopitant, CGP49823, CP-122,721, CP-96,345, CP-99,994, FK 888, GR 82334, GR 94800, GR203040, GR-205171, GSK1144814, GSK206136, GSK424887, GW679769, HSP-117, L 703,606, L 732,138, L 733,060, L 742,694, L668,169, LY 303241, LY 303870, LY 306740, Maropitant, MEN 11149, Orvepitant, PD 154075, R-544, RP-67580, RPR 100893, SCH619734, Spantide II, Spantide III, Spendide, SR140333, Vestipitant, WIN-41,708, WIN-62,577, or a derivative, a variant, an analogue, a pharmaceutically acceptable salt, a tautomer or a pro-drug thereof.

5. A ~~method~~ use according to claim 3, wherein the NK2 receptor antagonist is selected from one or more of the group consisting of SR-48968, L-659877, GR103537, MGN-10627, SR144190 and GR94800, or a derivative, a variant, an analogue, a pharmaceutically acceptable salt, a tautomer or a pro-drug thereof.

6. A ~~method~~ use according to claim 3, wherein the NK3 receptor antagonist is selected from one or more of the group consisting of SR-143,801, R820, R486, SB222200, L758,298 and NKP608, or a derivative, a variant, an analogue, a pharmaceutically acceptable salt, a tautomer or a pro-drug thereof.

7. A ~~method~~ use according to any one of claims 1 to 6, wherein the substance P receptor antagonist is administered to the subject at a dose of 0.25 mg/kg to 25 mg/kg.

8. A ~~method~~ use according to any one of claims 1 to 7, ~~wherein the method~~for reduc~~es~~ing progression of the disease, condition or state associated with chronic traumatic encephalopathy.

~~9~~1. Use of a substance P receptor antagonist in the preparation of a medicament for preventing and/or treating a disease, condition or state associated with chronic traumatic encephalopathy.

~~10. A pharmaceutical composition when used to prevent and/or treat a disease, condition or state associated with chronic traumatic encephalopathy, the composition including a substance P receptor antagonist.~~

~~11. A pharmaceutical composition according to claim 10, wherein the substance P receptor antagonist is a NK1 receptor antagonist, a NK2 receptor antagonist, or a NK3 receptor antagonist.~~

~~12. A pharmaceutical composition according to claim 11, wherein the NK1 receptor antagonist is selected from one or more of the group consisting Casopitant, CGP49823, CP-122,721, CP-96,345, CP-99,994, FK-888, GR-82334, GR-94800, GR203040, GR-205171, GSK1144814, GSK206136, GSK424887, GW679769, HSP-117, L-703,606, L-732,138, L-733,060, L-742,694, L668,169, LY-303241, LY-303870, LY-306740, Maropitant, MEN-11149, Orvepitant, PD-154075, R-544, RP-67580, RPR-100893, SCH619734, Spantide II, Spantide III, Spendide, SR140333, Vestipitant, WIN-41,708, WIN-62,577, or a derivative, a variant, an analogue, a pharmaceutically acceptable salt, a tautomer or a pro-drug thereof.~~

~~13. A pharmaceutical composition according to claim 11, wherein the NK2 receptor antagonist is selected from one or more of the group consisting of SR-48968, L-659877, GR103537, MGN-10627, SR144190 and GR94800, or a derivative, a variant, an analogue, a pharmaceutically acceptable salt, a tautomer or a pro-drug thereof.~~

~~14. A pharmaceutical composition according to claim 11, wherein the NK3 receptor antagonist is selected from one or more of the group consisting of SR-143,801, R820, R486, SB222200, L758,298 and NKP608, or a derivative, a variant, an analogue, a pharmaceutically acceptable salt, a tautomer or a pro-drug thereof.~~

~~15. A pharmaceutical composition according to any one of claims 9 to 14, wherein the pharmaceutical composition is used for either or both of:~~

~~i) preventing and/or treating a disease, condition or state associated with chronic traumatic encephalopathy;~~

~~ii) inhibiting progression of a disease, condition or state associated with chronic traumatic encephalopathy.~~